Despite a recent FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to a decrease in CD4+ T-cells, Gilead Sciences (NASDAQ:GILD) has shown strong performance this year. Its stock ...

Generally speaking, I’m not a big fan of discussing biopharmaceutical firms such as Gilead Sciences (NASDAQ:GILD). While the sector is intriguing and offers bountiful opportunities, it’s also replete ...

After a disastrous performance in the first half of 2024, Gilead Sciences stock has rebounded strongly since mid-June. With Gilead Sciences due to report its Q2 results on Thursday, it's a good time ...

Gilead's stock is rated a "buy" due to its thriving HIV business, promising oncology pipeline, and potential for long-term growth despite some volatility. The company's Q3 earnings show strong ...